Study:
A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of Atorvastatin in Patients With Clinically Isolated Syndrome and High Risk of Conversion to Multiple Sclerosis (ITN020AI)
Rationale:
n/a
Purpose:
Patients who have been diagnosed with clinically isolated syndrome (CIS) often develop
problems related to the central nervous system, which controls the nerves in the body. Some
of these patients may later be diagnosed with multiple sclerosis (MS), a progressive disease
of the nervous system. The purpose of this study is to determine if the drug atorvastatin is
helpful to CIS patients.
Study hypothesis: Early intervention with atorvastatin in patients with CIS will result in a
state of immunological tolerance.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Multiple Sclerosis |
Drug: Atorvastatin
Drug: Placebo |
Phase 2 |
Verified by
National Institute of Allergy and Infectious Diseases (NIAID)
April, 2012
Sponsored by: National Institute of Allergy and Infectious Diseases (NIAID)
Information provided by: National Institute of Allergy and Infectious Diseases (NIAID)
ClinicalTrials.gov identifier: NCT00094172
Study Type: Interventional
Study Design: Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention
Cleveland Clinic Foundation
Cleveland, Ohio 44195
United States
Scott Zamvil, MD, PhD., Study Chair
Emmanuelle Waubant, MD, PhD., Study Chair